Enterprise Value

410.2M

Cash

555.7M

Avg Qtr Burn

-32.05M

Short % of Float

6.49%

Insider Ownership

4.35%

Institutional Own.

69.73%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
HEMGENIX® (etranacogene dezaparvovec-drlb) (AMT-061) Details
Hemophilia, Rare diseases, Rare genetic disease

Approved

Quarterly sales

AMT-130 Details
Huntington's disease, Genetic disorder

Phase 1/2

Data readout

AMT-260 Details
Epilepsy, Mesial temporal lobe epilepsy

Phase 1/2

Initiation

AMT-162 Details
Amyotrophic lateral sclerosis

Phase 1/2

Initiation

AMT-191 Details
Fabry disease, Genetic disorder

Phase 1/2

Initiation